Recombinant Chimeric Virus with Wild‐Type Dengue 4 Virus Premembrane and Envelope and Virulent Yellow Fever Virus Asibi Backbone Sequences Is Dramatically Attenuated in Nonhuman Primates
The Journal of Infectious Diseases2008Vol. 197(5), pp. 693–697
Citations Over TimeTop 10% of 2008 papers
Charles E. McGee, Mark G. Lewis, Marisa St. Claire, Wendeline Wagner, Jean Lang, Bruno Guy, Konstantin A. Tsetsarkin, Stephen Higgs, Thierry Decelle
Abstract
Candidate vaccine ChimeriVax viruses are attenuated, efficacious, safe, and highly unlikely to be transmitted by arthropod vectors. Nevertheless, concerns have been raised about the use of these vaccines because of the potential for recombination between vaccine and wild-type (WT) strains. To evaluate the vertebrate pathogenicity of such a worst-case recombinant, ChimeriVax-dengue (DEN) 4 virus was chimerized with the WT Asibi yellow fever virus. In this worst-case scenario, chimeric viruses remained fully attenuated in nonhuman primates. We therefore conclude that, even in the highly unlikely event of "virulent" backbone reversion, the safety of ChimeriVax-DEN vaccines would not be compromised.
Related Papers
- → Dengue Virus-Specific and Flavivirus Group Determinants Identified with Monoclonal Antibodies by Indirect Immunofluorescence(1982)444 cited
- → An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design(2017)73 cited
- → Neutralization Assay for Zika and Dengue Viruses by Use of Real-Time-PCR-Based Endpoint Assessment(2017)37 cited
- → Determination of dengue virus serotypes in individual Aedes aegypti mosquitoes in Colombia(1998)30 cited
- → Present situation and progress in yellow fever attenuated live vaccine(2018)